Business
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), were recently published in the top-tier oncology journal Annals of Oncology (IF:65.4). The publicati
About this update from Alphamab Oncology
[{"type":"text","content":"SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), were recently published in the top-tier oncology journal Annals of Oncology (IF:65.4). The publication is titled: "Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial". The study was led by Professor Jianming Xu and his team from the Chinese PLA General Hospital as the principal investigators.","length":849,"tagName":"p"},{"type":"text","content":"Annals of Oncology is the official journal of the European Society for Medical Oncology (ESMO) and the Japanese Society of Medical Oncology (JSMO). It is dedicated to publishing groundbreaking oncology and translational research that changes clinical practice and improves patient outcomes. With an outstanding impact factor of 65.4, the journal is committed to advancing the standards of cutting-edge research, accelerating the exploration of novel technologies, and facilitating their clinical application worldwide.","length":518,"tagName":"p"},{"type":"text","content":"This study is a randomized, double-blind, controlled, multicenter Phase III clinical trial (NCT05427383) aiming at evaluating the efficacy and safety of anbenitamab combined with chemotherapy versus standard treatment in patients with HER2-positive GC/GEJ who had previously failed first-line therapy containing trastuzumab. The study enrolled patients with HER2-positive GC/GEJ who had disease progression after at least first-line trastuzumab-based treatment. Enrolled patients were randomized in a 1:1 ratio to receive either anbenitamab combined with chemotherapy (Anbenitamab Group) or standard-of-care therapy (SOC Control Group). Randomization was stratified according to the combined chemotherapy (taxane or irinotecan), HER2 expression (IHC 3+ or IHC 2+ with FISH amplification), and previous lines of therapy (1 or ≥2). The primary efficacy endpoints were progression-free survival...